SoftBank posts record £19bn loss as tech investments flop


UPDATE 1-Pfizer to boost pipeline with $5.4 bln Global Blood Therapeutics buy

Pfizer Inc will buy blood disorder drugmaker Global Blood Therapeutics in a $5.4 billion deal, as it looks to boost its pipeline to combat a potential slowdown in COVID product demand that analysts anticipate from falling cases. New York-based Pfizer, flush with cash from sales of its COVID-19 vaccine last year, has been on the lookout for acquisitions that could bring in billions in annual sales by the end of the decade. Pfizer said on Monday it will pay $68.50 per Global Blood share, representing a premium of about 7.3% to the stock’s closing price on Friday.

Leave a Reply

Your email address will not be published. Required fields are marked *